Enterprise Value
758.9M
Cash
130.4M
Avg Qtr Burn
-21.8M
Short % of Float
7.93%
Insider Ownership
1.51%
Institutional Own.
41.01%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ibsrela (Tenapanor) (NHE3 sodium transport inhibitor) Details Irritable bowel syndrome, Constipation | Approved Quarterly sales | |
XPHOZAH (Tenapanor) (Phosphate Absorption Inhibitor) Details Electrolyte disorder, Hyperphosphatemia, Kidney disease, Chronic kidney disease | PDUFA Approval decision | |
RDX013 Details Hyperkalemia | Phase 2 Update |